Trends & Insights: February 2026 – A pharmaphorum industry report

From Eli Lilly revealing its fourth new manufacturing site in a $27 billion capital investment spree in the US – a $3.5 billion facility in Lehigh Valley, Pennsylvania – to the FDA starting to accept requests to participate in its PreCheck pilot programme, designed to make it easier and quicker for pharma companies to set up manufacturing facilities in the US, and to the Trump administration's long-promised direct-to-consumer (DTC) sales channel for medicines, TrumpRx, finally going live, as well as Texas Attorney General Ken Paxton filing a lawsuit against Sanofi, claiming the company bribed doctors to prescribe its medicines – pharmaphorum reported on the life sciences industry across the board in February.

So, while we wrote that there are signs that Biogen and Eisai's Alzheimer's disease Leqembi therapy is finally gathering some momentum commercially, that PTC Therapeutics abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy (DMD) treatment Translarna, after the FDA said it was unlikely to approve the drug based on the submitted data, and that a psychoactive ingredient found in ayahuasca, a brew used in shamanistic rituals in South America, has shown promise as a treatment for depression in a phase 2a trial – we were also well aware of the myriad other news releases out there, too.

Indeed, outside of pharmaphorum’s main reportage in February, the life sciences news flow pointed to an industry moving beyond experimentation and into a phase of innovation more focused on execution. Across pharmaceuticals, biotech, and healthcare technology, announcements were characterised by late stage regulatory progress, large scale manufacturing investment, and the operational deployment of digital tools, rather than early stage discovery alone.

From FDA approvals that materially shift standards of care, to hundreds of millions committed to biomanufacturing infrastructure, and from AI platforms scaling into routine use to sustained commercial growth in specialist portfolios, the month illustrated how competitive advantage in 2026 is increasingly shaped by delivery, not just discovery.

1. Regulatory decision making accelerates, with clear expectations

February saw several regulatory milestones that signal how approval pathways are evolving faster, but with clear demands for robust outcomes and differentiated value.

Novocure’s FDA approval for Optune Pax in locally advanced pancreatic cancer was particularly notable. The decision followed data from the Phase III PANOVA 3 trial, in which its Tumour Treating Fields device improved median overall survival and significantly delayed pain progression without adding chemotherapy associated systemic toxicity. In an indication where treatment options have scarcely evolved for decades, the approval underlines regulators’ willingness to recognise non pharmacological modalities when survival and quality of life benefits are clearly demonstrated.

In haematology, AstraZeneca’s approval of Calquence plus venetoclax as the first all oral, fixed duration regimen for first line chronic lymphocytic leukaemia echoed a broader regulatory appetite for regimens that reduce long term treatment burden. With 77% of patients progression free at three years in the AMPLIFY trial, and treatment deliberately capped at 14 months, the decision reflects payer and patient priorities alongside clinical efficacy.

Regulators also continued to apply expedited mechanisms selectively. The FDA’s acceptance of Takeda and Protagonist Therapeutics’ NDA for rusfertide – accompanied by Priority Review, Breakthrough Therapy, and Orphan Drug designations – reflects sustained support for therapies that address both disease biology and treatment burden, in this case by reducing the need for repeated phlebotomy in polycythaemia vera.

2. Manufacturing strategy moves from operations to boardroom priority

If January emphasised supply chain resilience, February made clear that manufacturing capacity itself is now a strategic asset.

FUJIFILM Biotechnologies’ £400m expansion of its Teesside site stood out not only for its scale, but for its positioning. By creating the UK’s largest single use biopharmaceutical CDMO facility and pairing it with a Bioprocess Innovation Centre, FUJIFILM signalled that future competitiveness lies in flexibility, speed, and integrated development to manufacturing pathways. The project also aligned closely with UK government life sciences ambitions, highlighting how industrial policy and corporate investment are increasingly intertwined.

Elsewhere, Zydus Lifesciences’ acquisition of Agenus’ California biologics facilities (PDF) and Cellares’ plans for automated cell therapy manufacturing in Leiden reinforced the same message: control over advanced therapy capacity is becoming a differentiator, particularly as cell, gene, and radiopharmaceutical pipelines mature.

This trend mirrors developments in US policy, where AbbVie’s $100 billion domestic investment agreement explicitly linked manufacturing expansion to pricing flexibility and tariff relief – a clear signal that governments expect life sciences companies to anchor innovation locally.

3. Innovation concentrates on high impact niches

February’s clinical updates showed continued concentration of innovation in rare disease, oncology, and CNS disorders, often backed by platform technologies or biomarker driven strategies.

Rare Disease Month provided context for announcements from OS Therapies, which reported positive immune biomarker data for OST HER2 in osteosarcoma – a rare paediatric cancer with historically limited therapeutic progress. While early, the data reflects a broader push to combine immunology with rare oncology targets, supported by policy incentives.

In precision oncology, Akiram Therapeutics’ AKIR001 gained high profile academic validation as the featured study in The Journal of Nuclear Medicine. The radiopharmaceutical’s preclinical tumour selective uptake and favourable dosimetry strengthen confidence as it advances through first in human trials, highlighting continued momentum behind targeted radiotherapies.

CNS innovation also remained active. Annovis Bio’s DSMB clearance for the Phase III Alzheimer’s trial of buntanetap allowed development to proceed uninterrupted, while German biotech FundaMental Pharma showcased preclinical data for FMP374, positioning dual acting NMDAR modulation as a potential next step beyond existing ketamine derived therapies in treatment resistant depression.

4. AI and data platforms shift decisively into execution mode

Digital health stories in February moved away from conceptual potential and toward scaled deployment and commercialisation.

Brainomix’ $25.4m Series C extension to fund US expansion illustrated how AI imaging tools are transitioning into routine clinical workflows. Its FDA cleared Brainomix 360 Stroke platform has already demonstrated improved thrombectomy decision making in real world settings, showing the measurable impact regulators and providers expect from AI adoption.

On the commercial side, Within3’s launch of Dataverse reflected growing sophistication in life sciences data strategy. By integrating real world data, claims, and structured HCP insights directly into launch intelligence workflows, the platform aims to close the gap between strategy and field execution – a recurring pain point for pharmaceutical launches.

SEQSTER’s 1 Click Data Refinery further reinforced a shift in narrative: the limiting factor for clinical AI is no longer model capability, but the availability of clean, regulatory grade data. The focus has moved firmly towards infrastructure.

5. Commercial performance rewards focus and depth

Alongside innovation headlines, February’s financial updates underlined the value of therapeutic focus.

Almirall’s 2025 results – €1.1 billion in net sales and EBITDA growth exceeding 20% – were driven almost entirely by its specialist dermatology strategy. Strong performance from biologics such as Ilumetri and Ebglyss, coupled with continued double digit growth from established brands, illustrated how depth in a defined therapeutic area can sustain both revenue and R&D investment.

The company’s decision to reinvest more than 12% of sales into pipeline development reflects a disciplined loop between commercial execution and future growth – a model echoed across other specialist players this month.